Egfr Test-Guided Erlotinib Versus Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Budget Impact Analysis

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.03.638
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy

BMJ Open
Medicine
2015English

Pcn76 - Budget Impact Analysis of Afatinib for the First-Line Treatment of Advanced or Metastatic Non–small-Cell Lung Cancer in China

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Impact of Initial Gefitinib or Erlotinib Versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Clinical Cancer Research
Cancer ResearchOncology
2012English

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Pcn44 - First-Line Treatment Efficacy in Egfr-Positive Non-Small Cell Lung Cancer: A Network Meta-Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Analysis of Continuous First‑line Treatment With Docetaxel and Carboplatin for Advanced Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2014English

Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared With Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer

PLoS ONE
Multidisciplinary
2014English

Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Network Meta-Analysis

Immunotherapy
OncologyAllergyImmunology
2019English

Efficacy of Bevacizumab Plus Erlotinib Versus Erlotinib Alone in Advanced Non-Small-Cell Lung Cancer After Failure of Standard First-Line Chemotherapy (BeTa): A Double-Blind, Placebo-Controlled, Phase 3 Trial

The Lancet
Medicine
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy